All insightsOctober 30, 2026

MedTech Industry Pulse: October 2026 Regulatory and Digital Health Roundup

October brought FDA's FY 2027 guidance priorities, a draft IDE electronic template, new AI software classifications, the end of Medicare's breakthrough pass-through shortcut, the EU's first device joint clinical assessments and UK long-term CE recognition.

October 2026 marked the start of a new regulatory year for medical-device, digital-health and diagnostics teams. FDA's fiscal year 2027 began on October 1, and the month's developments pointed in one consistent direction: regulators are standardizing how evidence is submitted, and they are shifting oversight of software and AI toward the full product lifecycle.

In the United States, FDA published its FY 2027 guidance priorities, proposed a structured electronic template for Investigational Device Exemption applications and issued a group of De Novo classification orders for software-driven devices. On the payment side, the end of the breakthrough-device shortcut for outpatient pass-through applications took effect. Europe began its first joint clinical assessments of medical devices, and the United Kingdom confirmed long-term recognition of CE-marked devices while setting out a lifecycle approach to AI regulation.

For MedTech leaders, the practical message is clear: evidence must be organized early, AI claims must be supported across the product's working life, and US, EU and UK market-access plans now each have new fixed points to plan around.

US regulatory focus: FDA sets its FY 2027 guidance agenda

At the start of the fiscal year, CDRH posted its proposed guidance documents for FY 2027. The A-list names the guidance FDA intends to publish during the year; the B-list names guidance it will publish as resources permit.

Software, artificial intelligence and cybersecurity dominate the lists. Priorities include finalizing the marketing-submission and lifecycle-management recommendations for AI-enabled device software functions, drafting evidentiary recommendations for generative AI-enabled conversational devices for mental disorders and finalizing the robotically assisted surgical-device premarket guidance issued in draft on September 25. FDA is accepting feedback on its priorities through November 30, 2026.

The list is a planning signal, not a guarantee. Still, it tells development teams where FDA expects to clarify its expectations next. Teams building AI-enabled functions should align their design controls, data management and change-control plans with the January 2025 draft lifecycle guidance now, rather than waiting for the final version. The CAHIR PCCP guide explains how a Predetermined Change Control Plan fits into that lifecycle approach.

IDE applications are moving toward a structured electronic template

On October 28, FDA announced a draft guidance for an electronic submission template for Investigational Device Exemption applications. Comments are due December 28, 2026.

The proposal follows the September draft template for PMA applications and FDA's established eSTAR program for 510(k) and De Novo requests. Together, these steps show FDA moving the main device submission types toward structured, consistent electronic content.

For sponsors planning a pivotal or early feasibility study, the template matters before the clinical protocol is final. A structured IDE asks for device description, risk analysis, prior testing, investigational plan, monitoring and informed-consent content in a set format. Gaps in bench testing, risk controls or study design become visible sooner. Teams should map their current IDE content against the draft and confirm who owns each section. The eSTAR 510(k) submission-readiness guide offers a practical model for running a structured-submission review.

Drug-delivery devices: revised performance-characteristics draft

On October 30, FDA issued a revised draft guidance on essential drug-delivery performance characteristics for devices that deliver drugs and biological products, revising the June 2024 draft. The comment period runs through January 28, 2027.

The guidance applies to products such as prefilled syringes, autoinjectors, on-body injectors, infusion pumps, inhalers and nasal sprays, including drug-device combination products. It asks manufacturers to identify the system-level functions needed to deliver the intended dose to the intended site, and to set specifications, acceptance criteria, verification and validation methods and control strategies for each.

Combination-product teams should check that these characteristics are traceable through design inputs, risk management and production controls under the Quality Management System Regulation. The QMSR resources on the Cahir MedTech blog and the toolkits library can help teams organize that evidence.

AI and software devices: new classifications and lifecycle direction

FDA continued to publish De Novo classification orders in October that create new Class II device types with special controls. They include software-aided adjunctive diagnostic devices for lesions suspicious for skin cancer and radiology software for referral of findings related to fibrotic lung disease, both published October 30.

These orders matter to later entrants. Once a device type is classified, later manufacturers can use the 510(k) pathway with the classified device as a predicate, but they must meet the listed special controls. Teams with similar software should read the special controls closely; they are a direct statement of the performance testing, labeling and software documentation FDA expects.

FDA also finalized a 510(k) exemption for certain Class II clinical toxicology test systems on October 6, subject to the limitations in the order. Diagnostics manufacturers should confirm whether their products fall within the exemption before changing their premarket plans.

For generative AI, FDA's discussion paper on generative AI-enabled medical devices remains the central reference. It is not draft guidance, but its questions on risk assessment, premarket evaluation and postmarket monitoring show where FDA's thinking is heading.

Medicare payment: the breakthrough pass-through shortcut has ended

CMS's FY 2027 inpatient payment final rule repealed the alternative pathway that let FDA Breakthrough Devices qualify for supplemental payments without separately showing substantial clinical improvement. For outpatient device pass-through payment, the repeal applies to applications received on or after October 1, 2026. For inpatient new technology add-on payments, it applies starting with FY 2028 applications.

This is a significant change for breakthrough-designated technologies. A Breakthrough designation no longer substitutes for comparative clinical evidence when a manufacturer seeks extra hospital payment. Evidence plans should now include outcomes that can show substantial clinical improvement over existing treatments, not only safety and effectiveness for FDA.

At the same time, CMS's proposed RAPID coverage pathway closed for comments on October 13. RAPID addresses national coverage for qualifying breakthrough devices; it does not restore the payment shortcut. Coverage and payment remain separate decisions with separate evidence standards. The medical device market-access guide and MedTech Compass help teams plan both.

Europe: the first joint clinical assessments of medical devices begin

On October 6, the European Commission selected the first two medical devices for joint clinical assessment under the EU Health Technology Assessment Regulation. Both are transcatheter mitral valve replacement systems: the Edwards Lifesciences SAPIEN M3 system and the Highlife trans-septal system. The Commission expects to select devices for joint clinical assessment on a quarterly basis.

This is the start of joint EU-level clinical assessment for high-risk devices. Member States will use the resulting reports in their own pricing and reimbursement decisions. On October 26, the Commission also published updated procedural guidance for joint scientific consultations on medical devices and IVDs, which gives developers an earlier route to discuss evidence plans with HTA bodies.

Separately, manufacturers of implantable and Class III devices, and Class C and D IVDs, should prepare for the transfer of SSCP and SSP uploads in EUDAMED from notified bodies to manufacturers, as set out in MDCG 2026-4.

United Kingdom: CE recognition confirmed and AI regulation reset

On October 21, the UK government confirmed it will continue to accept CE-marked medical devices and IVDs on a long-term basis in Great Britain, following a public consultation. The UKCA route remains the domestic approval pathway. For manufacturers, this removes a major source of uncertainty in Great Britain launch planning, although post-market surveillance and registration duties still apply.

AI regulation also moved forward. On October 6, the government accepted all 44 recommendations of the National Commission into the Regulation of AI in Healthcare, backing a proportionate, lifecycle-based framework, and the MHRA opened applications for the third phase of its AI Airlock regulatory sandbox. On October 14, the MHRA published its MHRA Strategy 2030, which includes an adaptive framework for AI as a medical device and wider reliance routes with trusted regulators, including FDA. The agency then presented that agenda to US industry at AdvaMed 2026.

What MedTech teams should do next

First, compare AI and software development plans with FDA's FY 2027 priorities and the UK's lifecycle direction. Data management, subgroup performance, change control and post-market monitoring should be documented, not assumed.

Second, prepare for structured submissions. IDE, PMA and 510(k) teams should organize evidence so that a structured template does not expose avoidable gaps late in the program.

Third, rebuild payment evidence plans for breakthrough-designated devices. Substantial clinical improvement now has to be shown directly for pass-through and add-on payments.

Fourth, for EU launches of high-risk devices, add joint clinical assessment and joint scientific consultation to the evidence timeline.

Finally, update Great Britain plans to reflect long-term CE recognition, and keep separate assumptions for FDA, CMS, the EU and the MHRA.

October 2026 MedTech pulse: quick answers

What were the most important medtech regulatory updates in October 2026?

The main updates were FDA's FY 2027 guidance priorities, a draft electronic submission template for IDE applications, new De Novo classifications for AI-enabled software, the end of the breakthrough-device shortcut for Medicare outpatient pass-through payment, the first EU joint clinical assessments of medical devices and the UK's long-term recognition of CE-marked devices.

When are comments due on FDA's draft IDE electronic submission template?

FDA's Federal Register notice lists a comment deadline of December 28, 2026.

Does FDA Breakthrough Device designation still qualify a device for extra Medicare payment?

Not on its own. For outpatient pass-through applications received on or after October 1, 2026, and for inpatient add-on payment applications from FY 2028, breakthrough devices must show substantial clinical improvement like other technologies.

Will the UK keep accepting CE-marked medical devices?

Yes. On October 21, 2026, the UK government confirmed it will continue to accept CE-marked medical devices and IVDs in Great Britain on a long-term basis, alongside the UKCA route.

Which medical devices were first selected for EU joint clinical assessment?

On October 6, 2026, the European Commission selected two transcatheter mitral valve replacement systems: the Edwards Lifesciences SAPIEN M3 system and the Highlife trans-septal system.

The October signal

The October 2026 MedTech pulse is a shift toward structured evidence and lifecycle oversight. Electronic templates link submission quality to how evidence is organized. AI classifications and guidance priorities link authorization to ongoing performance. Medicare payment now links breakthrough status to comparative clinical evidence. European HTA and UK recognition decisions link market access to new, fixed regional processes.

The teams best positioned for 2027 will build one operating model that connects product strategy, regulatory evidence, quality, reimbursement and post-market intelligence. Read last month's September 2026 MedTech pulse for the robotics, PMA and coverage developments that led into October.

Explore the CAHIR MedTech product suite for regulatory execution and global medical-device market intelligence. Use MedTech Copilot to draft and manage lifecycle evidence, and MedTech Compass to evaluate reimbursement, competitive position and market priorities.